NCT00133185已完成3 期
A Randomized, Double-Blind, Parallel-Group Assessment of the Safety and Efficacy of Telmisartan 40mg Plus Hydrochlorothiazide 12.5 mg in Comparison With Losartan 50 mg Plus Hydrochlorothiazide 12.5 mg in Taiwanese Patients With Mild to Moderate Hypertension
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 31
- 试验地点
- 2
- 主要终点
- Change from baseline in sitting diastolic blood pressure (DBP) at trough (24 hours post-dosing) at the last observation during the double-blind phase.
研究概览
简要总结
The primary objective of this trial is to compare the efficacy and safety of telmisartan 40 mg/hydrochlorothiazide 12.5mg (Micardis Plus) with that of losartan 50 mg/hydrochlorothiazide 12.5 mg, a reference AIIA combined with diuretic, in Taiwanese patients with mild to moderate hypertension.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 20 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Mild to moderate hypertension as defined by a morning mean(>95 and <115mmHg) of two diastolic blood pressure measurements (DBP) after 5 min in the sitting position following a minimum 2-week placebo run in phase.Mean sitting systolic blood pressure (SBP) must be >140 and <200mmHg. The mean DBP and SBP values are calculated as the mean of the two sitting measurements taken 2 min apart just before the drug intake.
- •Male or female between 20 to 80 years old
- •Ability to provide written informed consent.
排除标准
- •Patients are still taking more than three anti-hypertensives at the screening visit
- •Pre-menopausal women
- •Known or suspected secondary hypertension
- •Mean sitting DBP<95mmHg and/or mean sitting SBP > 200mmHg at the end of placebo run-in phase
- •Hepatic and/or renal dysfunction
- •Known bilateral renal artery stenosis, patient with a solitary kidney, post renal transplant
- •Known NYHA functional class Chronic Heart Failure (CHF) III, IV
- •Unstable angina, myocardial infarction, cardiac surgery or stroke within the preceding six months
- •Post-Transluminal Coronary Angioplasty(PTCA) within the preceding three months
- •Sustained ventricular tachycardia, atria fibrillation, second or third degree AV block, VPC or APC (>10% of heart rate) or other clinically relevant cardiac arrhythmia as determined by the clinical investigator
- •Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of aortic or mitral valve.
- •Once documented evidence by ophthalmological examination of significant retinal haemorrhages/ exudates
- •Clinically significant sodium depletion as defined by serum sodium level less than 130 mmol/L
- •Clinically significant hyperkalemia as defined by serum potassium level >5.5 mmol/L
- •Non-insulin dependent DM poorly controlled whicih is defined as HbA1c>8% twice consecutively within 6 months and/or AC blood sugar>180 mg/dl.
- •Insulin Dependent Diabetes Mellitus
- •Chronic administration of oral anticoagulants and/or digoxin within the past 6 months.
- •Known drug or alcohol dependency
- •Administration of medication known to affect blood pressure, except medication allowed by the protocol
- •Angioedema with ACE inhibitors
- •Use of nitrates
结局指标
主要结局
Change from baseline in sitting diastolic blood pressure (DBP) at trough (24 hours post-dosing) at the last observation during the double-blind phase.
时间窗: 8 weeks
次要结局
- Change from baseline in sitting SBP, standing DBP, standing SBP, sitting and standing heart rate at trough as well as blood pressure control and blood pressure response as defined in study protocol at the last observation will be evaluated.(8 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
4 期
Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 HypertensionHypertensionNCT00168779Boehringer Ingelheim1,185
已完成
4 期
A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II PatientsHypertensionNCT00240448Boehringer Ingelheim1,109
已完成
3 期
Combination of Telmisartan 40 mg Plus Hydrochlorothiazide (HCTZ) 12.5 mg vs. Telmisartan 40 mg Alone in Patients With Essential Hypertension Who Fail to Respond Adequately to Telmisartan MonotherapyHypertensionNCT00144222Boehringer Ingelheim218
终止
4 期
SAFE-CRP: Structural Alterations and Function of Endothelium in Cardiovascular Risk PatientsCoronary ArteriosclerosisHypertensionNCT00274105Boehringer Ingelheim22
已完成
4 期
Study to Evaluate Efficacy of Micardis® (Telmisartan) and Valsartan in Patients With Mild-to-moderate Hypertension After Missing One Dose Using Ambulatory Blood Pressure MonitoringHypertensionNCT02242318Boehringer Ingelheim440